EU Animal Products Ban Threatens US Sales

9 December 1997

With 80% of oral medicines containing animal by-products banned by theEuropean Union as of January 1, 1998 (Marketletters passim), US health officials say the policy will threaten domestic, as well as overseas supplies. If the ban is not amended, the change of ingredients is such that there would be shortages everywhere, said Sharon Smith Holston, Food and Drug Administration deputy commissioner.

Almost all pills/capsules now contain tallow made from animal bones, and to comply with the ban, firms would need to find suppliers who produced it from animals specially slaughtered. While drugmakers contend that transmissible spongiform encephalopathies have never been found in tallow or gelatin, the Pharmaceutical Research and Manufacturers of America said that in a worst-case estimate, there would be a one-in-a-billion risk.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight